keyword
MENU ▼
Read by QxMD icon Read
search

Yttrium-90

keyword
https://www.readbyqxmd.com/read/29331342/development-of-a-prognostic-score-to-predict-response-to-yttrium-90-radioembolization-for-hepatocellular-carcinoma-with-portal-vein-invasion
#1
Carlo Spreafico, Carlo Sposito, Marta Vaiani, Tommaso Cascella, Sherrie Bhoori, Carlo Morosi, Rodolfo Lanocita, Raffaele Romito, Carlo Chiesa, Marco Maccauro, Alfonso Marchianò, Vincenzo Mazzaferro
BACKGROUND & AIMS: Yttrium-90 trans-arterial radioembolization (TARE) has shown promising efficacy in the treatment of patients with hepatocellular carcinoma (HCC) associated with tumoral portal vein thrombosis (PVTT). Aim of this study is to identify prognostic factors for survival in patients with HCC and PVTT undergoing TARE, and build a prognostic classification for these patients. METHODS: This is a single Center retrospective study conducted over 6 years (2010-2015), on consecutive patients undergoing TARE...
January 10, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29329568/prospective-longitudinal-quality-of-life-and-survival-outcomes-in-patients-with-advanced-infiltrative-hepatocellular-carcinoma-and-portal-vein-thrombosis-treated-with-yttrium-90-radioembolization
#2
Minzhi Xing, Nima Kokabi, Juan C Camacho, Hyun S Kim
BACKGROUND: To determine the effect of Yttrium-90 (Y90) radioembolization on health-related quality of life (HRQOL) and its effect on overall survival advanced, unresectable infiltrative hepatocellular carcinoma (HCC) patients with concurrent portal vein thrombosis (PVT). METHODS: Consecutive patients with unresectable infiltrative HCC and PVT were recruited. The Short-Form 36 (SF-36) questionnaire was used to assess HRQOL for consecutive patients treated with glass-based Y90 based on a prospective phase II trial...
January 12, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29306542/prospective-study-to-determine-early-hypertrophy-of-the-contra-lateral-liver-lobe-after-unilobar-yttrium-90-selective-internal-radiation-therapy-in-patients-with-hepatocellular-carcinoma
#3
Jin Yao Teo, John Carson Allen, David Chee Eng Ng, Julianah Bee Abdul Latiff, Su Pin Choo, David Wai-Meng Tai, Albert Su Chong Low, Foong Koon Cheah, Jason Pik Eu Chang, Juinn Huar Kam, Victor T W Lee, Alexander Yaw Fui Chung, Chung Yip Chan, Pierce Kah Hoe Chow, Brian K P Goh
BACKGROUND: Liver resection is a major curative option in patients presenting with hepatocellular carcinoma. An inadequate functional liver remnant is a major limiting factor precluding liver resection. In recent years, hypertrophy of the functional liver remnant after selective internal radiation therapy hypertrophy has been observed, but the degree of hypertrophy in the early postselective internal radiation therapy period has not been well studied. METHODS: We conducted a prospective study on patients undergoing unilobar, Yttrium-90 selective internal radiation therapy for hepatocellular carcinoma to evaluate early hypertrophy at 4-6 weeks and 8-12 weeks after selective internal radiation therapy...
January 3, 2018: Surgery
https://www.readbyqxmd.com/read/29299370/safety-of-selective-internal-radiation-therapy-sirt-with-yttrium-90-microspheres-combined-with-systemic-anticancer-agents-expert-consensus
#4
REVIEW
Andrew Kennedy, Daniel B Brown, Jonas Feilchenfeldt, John Marshall, Harpreet Wasan, Marwan Fakih, Peter Gibbs, Alexander Knuth, Bruno Sangro, Michael C Soulen, Gianfranco Pittari, Ricky A Sharma
Selective internal radiation therapy (SIRT) with microspheres labelled with the β-emitter yttrium-90 (Y-90) enables targeted delivery of radiation to hepatic tumors. SIRT is primarily used to treat inoperable primary or metastatic liver tumors. Eligible patients have usually been exposed to a variety of systemic anticancer therapies, including cytotoxic agents, targeted biologics, immunotherapy and peptide receptor radionuclide therapy (PRRT). All these treatments have potential interactions with SIRT; however, robust evidence on the safety of these potential combinations is lacking...
December 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29290464/complex-upper-arm-reconstruction-using-an-antero-lateral-thigh-free-flap-after-an-extravasation-of-yttrium-90-ibritumomab-tiuxetan-a-case-report-and-literature-review
#5
A Baus, C Keilani, C-S Bich, F Entine, M Brachet, P Duhamel, J-C Amabile, J V Malfuson, E Bey
Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) is used in the treatment of non- Hodgkin's lymphoma. Extravasation is an iatrogenic complication that is fortunately rare. However, the treatment of this complication is often complex due to the risk of extensive skin necrosis and unpredictable evolution of localized irradiation. This vesicant drug requires emergency management when extravasation occured. Radiations burns have specificities. Therefore, wound coverage involves specific plastic surgical techniques. Here, we report the case of a man presenting a chronic and extensive skin necrosis of upper arm treated with an antero-lateral thigh free flap...
December 28, 2017: Annales de Chirurgie Plastique et Esthétique
https://www.readbyqxmd.com/read/29285636/the-effect-of-selective-internal-radiation-therapy-with-yttrium-90-resin-microspheres-on-lung-carbon-monoxide-diffusion-capacity
#6
Tunc Ones, Emel Eryuksel, Feyyaz Baltacioglu, Berrin Ceyhan, Tanju Yusuf Erdil
BACKGROUND: Selective internal radiation therapy (SIRT) with embolization of branches of the hepatic artery is a valuable therapeutic tool for patients with hepatic malignancies; however, it is also associated with lung injury risk due to shunting. Diffusion capacity of the lungs for carbon monoxide (DLCO) is a clinically significant lung function test, and worsening in DLCO is suggested to reflect a limited gas exchange reserve caused by the potential toxicity of chemoradiotherapy or it may be a marker of related lung injury...
December 29, 2017: EJNMMI Research
https://www.readbyqxmd.com/read/29251517/yttrium-90-resin-microspheres-and-their-use-in-the-treatment-of-intrahepatic-cholangiocarcinoma
#7
Luca Filippi, Orazio Schillaci, Roberto Cianni, Oreste Bagni
Intrahepatic cholangiocarcinoma (ICC) is a severe and rapidly progressive hepatic tumor. Surgery is often impracticable due to locally advanced presentation. On the other hand, chemotherapy has demonstrated only limited effectiveness. For these reasons, liver-directed therapies have been successfully applied for treating ICC. In particular, radioembolization with Yttrium-90 (90Y)-labeled spheres has been reported to be a promising therapeutic approach for this neoplasia. Two commercial forms of 90Y-labeled spheres are available: glass (TheraSphere®) and resin (SIR-Spheres®) microspheres...
December 18, 2017: Future Oncology
https://www.readbyqxmd.com/read/29204055/combined-treatment-of-pancreatic-cancer-xenograft-with-90y-itga6b4-mediated-radioimmunotherapy-and-pi3k-mtor-inhibitor
#8
Winn Aung, Atsushi B Tsuji, Hitomi Sudo, Aya Sugyo, Yoshinori Ukai, Katsushi Kouda, Yoshikazu Kurosawa, Takako Furukawa, Tsuneo Saga, Tatsuya Higashi
AIM: To investigate the therapeutic effect of combined integrin α6β4-targeted radioimmunotherapy (RIT) and PI3K/mTOR inhibitor BEZ235 in a pancreatic cancer model. METHODS: Phosphorylation of Akt, mTOR, the downstream effectors eukaryotic initiation factor 4E binding protein 1 (4EBP1) and S6 ribosomal protein (S6) were evaluated in BxPC-3 human pancreatic cancer cells treated with Yttrium-90 (90Y) labeled anti-integrin α6β4 antibody (ITGA6B4) and BEZ235 by western blotting...
November 14, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29184683/selective-internal-radiation-therapy-using-yttrium-90-resin-microspheres-in-patients-with-unresectable-hepatocellular-carcinoma-a-retrospective-study
#9
Parvez S Mantry, Ashwini Mehta, Bahar Madani, Alejandro Mejia, Islam Shahin
Background: Selective internal radiation therapy (SIRT) with yttrium-90 resin (Y-90 resin) microspheres has been used as a locoregional therapy for patients with unresectable hepatocellular carcinoma (HCC). We examined patient and disease characteristics that might affect survival after Y-90 resin, as well as treatment tolerability. Methods: Data from patients with unresectable HCC treated with Y-90 resin at a single institution were reviewed retrospectively. Survival was assessed with Kaplan-Meier curves and log-rank tests...
October 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29181682/effectiveness-of-hepatic-artery-infusion-hai-versus-selective-internal-radiation-therapy-y90-for-pretreated-isolated-unresectable-colorectal-liver-metastases-iu-crclm
#10
Mashaal Dhir, Mazen S Zenati, Heather L Jones, David L Bartlett, M Haroon A Choudry, James F Pingpank, Matthew P Holtzman, Nathan Bahary, Melissa E Hogg, Herbert J Zeh, David A Geller, J Wallis Marsh, Allan Tsung, Amer H Zureikat
BACKGROUND: In the era of modern effective systemic chemotherapy, the comparative effectiveness of hepatic artery infusion (HAI) versus selective internal radiation therapy (yttrium-90 [Y90]) for pretreated patients with isolated unresectable colorectal liver metastasis (IU-CRCLM) remains unknown. This study sought to compare the overall survival (OS) after HAI versus Y90 for IU-CRCLM patients treated with modern chemotherapy and to perform a cost analysis of both regional methods. METHODS: This study retrospectively reviewed patients receiving HAI or Y90 in combination with modern chemotherapy as second-line therapy for IU-CRCLM...
November 27, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29158362/cd38-bispecific-antibody-pretargeted-radioimmunotherapy-for-multiple-myeloma-and-other-b-cell-malignancies
#11
Damian J Green, Shyril O'Steen, Yukang Lin, Melilssa L Comstock, Aimee L Kenoyer, Donald K Hamlin, D Scott Wilbur, Darrell R Fisher, Margaret Nartea, Mark D Hylarides, Ajay K Gopal, Theodore A Gooley, Johnnie J Orozco, Brian G Till, Kelly D Orcutt, K Dane Wittrup, Oliver W Press
Pretargeted radioimmunotherapy (PRIT) has demonstrated remarkable efficacy targeting tumor antigens, but immunogenicity and endogenous biotin blocking may limit clinical translation. We describe a new PRIT approach for the treatment of Multiple Myeloma (MM) and other B cell malignancies, for which we developed an anti-CD38 bispecific fusion protein that eliminates endogenous biotin interference and immunogenic elements. In murine xenograft models of MM and non-Hodgkin lymphoma (NHL), the CD38 bispecific construct demonstrated excellent blood clearance and tumor targeting...
November 20, 2017: Blood
https://www.readbyqxmd.com/read/29149442/assessment-of-the-relative-contribution-of-volume-and-concentration-changes-in-yttrium-90-labelled-resin-microspheres-on-ionization-chamber-measurements
#12
Nicholas Forwood, Kathy P Willowson, Michael Tapner, Dale L Bailey
No abstract text is available yet for this article.
December 2017: Australasian Physical & Engineering Sciences in Medicine
https://www.readbyqxmd.com/read/29147442/metastatic-malignant-paraganglioma-a-case-report-and-review-of-literature
#13
Carlo Angelo Prades, Bassel Atassi, Hamid Nazeer
Metastasis is a rare presentation of non-secretory paraganglioma. Consequently, there is no standard of care for the treatment of metastatic malignant paraganglioma. The most widely used chemotherapy regimen for non-resectable cases includes cyclophosphamide, vincristine, and dacarbazine (CVD). CVD has been previously studied with variable therapeutic response. However, yttrium-90 (Y90) radioembolization has not been previously studied in the treatment of hepatic metastasis in patients diagnosed with malignant paraganglioma...
June 2017: World Journal of Oncology
https://www.readbyqxmd.com/read/29113660/functional-hepatic-imaging-as-a-biomarker-of-primary-and-secondary-tumor-response-to-loco-regional-therapies
#14
REVIEW
H L Lewis, M A Ghasabeh, P Khoshpouri, I R Kamel, T M Pawlik
Objective criteria to measure tumor response are a key tenet for assessment of treatment efficacy when evaluating a therapeutic modality. Several response criteria have been proposed including the Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), RECIST 1-1, and European Association for the Study of the Liver (EASL) guidelines. Response following loco-regional therapies (LRT) can be particularly difficult to assess as post-treatment changes may not always relate to changes in lesion size...
December 2017: Surgical Oncology
https://www.readbyqxmd.com/read/29113030/recent-advances-in-transarterial-embolotherapies-in-the-treatment-of-hepatocellular-carcinoma
#15
Edward Wolfgang Lee, Sarah Khan
Management of hepatocellular carcinoma (HCC) can be maximized with the utilization of multiple treatment modalities including transplant, surgical resection and locoregional therapies including ablative therapies and transarterial embolotherapies. Although transplant and surgical resection offer the best clinical outcomes, a limited number of patients are amenable to these surgical treatment options due to the advanced disease at presentation. Transarterial embolotherapies including conventional transarterial chemoembolization (cTACE), bland transarterial embolization (TAE), drug-eluting beads transarterial chemoembolization (DEB-TACE) and selective internal radiation therapy (SIRT) with Yttrium 90 (90Y) have played an increasingly important role for these patients with unresectable HCC...
November 8, 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/29107680/grant-deny-or-reassess-the-role-of-yttrium-90-in-hepatocellular-carcinoma
#16
Ahmed Omar Kaseb
No abstract text is available yet for this article.
October 26, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29107679/efficacy-and-safety-of-selective-internal-radiotherapy-with-yttrium-90-resin-microspheres-compared-with-sorafenib-in-locally-advanced-and-inoperable-hepatocellular-carcinoma-sarah-an-open-label-randomised-controlled-phase-3-trial
#17
Valérie Vilgrain, Helena Pereira, Eric Assenat, Boris Guiu, Alina Diana Ilonca, Georges-Philippe Pageaux, Annie Sibert, Mohamed Bouattour, Rachida Lebtahi, Wassim Allaham, Hélène Barraud, Valérie Laurent, Elodie Mathias, Jean-Pierre Bronowicki, Jean-Pierre Tasu, Rémy Perdrisot, Christine Silvain, René Gerolami, Olivier Mundler, Jean-Francois Seitz, Vincent Vidal, Christophe Aubé, Frédéric Oberti, Olivier Couturier, Isabelle Brenot-Rossi, Jean-Luc Raoul, Anthony Sarran, Charlotte Costentin, Emmanuel Itti, Alain Luciani, René Adam, Maïté Lewin, Didier Samuel, Maxime Ronot, Aurelia Dinut, Laurent Castera, Gilles Chatellier
BACKGROUND: Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma. We aimed to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy (SIRT) with yttrium-90 ((90)Y) resin microspheres in patients with hepatocellular carcinoma. METHODS: SARAH was a multicentre, open-label, randomised, controlled, investigator-initiated, phase 3 trial done at 25 centres specialising in liver diseases in France. Patients were eligible if they were aged at least 18 years with a life expectancy greater than 3 months, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, Child-Pugh liver function class A or B score of 7 or lower, and locally advanced hepatocellular carcinoma (Barcelona Clinic Liver Cancer [BCLC] stage C), or new hepatocellular carcinoma not eligible for surgical resection, liver transplantation, or thermal ablation after a previously cured hepatocellular carcinoma (cured by surgery or thermoablative therapy), or hepatocellular carcinoma with two unsuccessful rounds of transarterial chemoembolisation...
October 26, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29097938/labelling-of-90-y-and-177-lu-dota-bioconjugates-for-targeted-radionuclide-therapy-a-comparison-among-manual-semiautomated-and-fully-automated-synthesis
#18
Michele Iori, Pier C Capponi, Sara Rubagotti, Luca Rosario Esposizione, Johanna Seemann, Riccardo Pitzschler, Thorsten Dreger, Debora Formisano, Elisa Grassi, Federica Fioroni, Annibale Versari, Mattia Asti
In spite of the hazard due to the radiation exposure, preparation of (90)Y- and (177)Lu-labelled radiopharmaceuticals is still mainly performed using manual procedures. In the present study the performance of a commercial automatic synthesizer based on disposable cassettes for the labelling of (177)Lu- and (90)Y-DOTA-conjugated biomolecules (namely, DOTATOC and PSMA-617) was evaluated and compared to a manual and a semiautomated approach. The dose exposure of the operators was evaluated as well. More than 300 clinical preparations of both (90)Y- and (177)Lu-labelled radiopharmaceuticals have been performed using the three different methods...
2017: Contrast Media & Molecular Imaging
https://www.readbyqxmd.com/read/29067511/safety-and-efficacy-of-transarterial-radioembolization-combined-with-chemoembolization-for-bilobar-hepatocellular-carcinoma-a-single-center-retrospective-study
#19
Joon Ho Kwon, Gyoung Min Kim, Kichang Han, Jong Yun Won, Man Deuk Kim, Do Yun Lee, Junhyung Lee, Woosun Choi, Yong Seek Kim, Do Young Kim, Kwang-Hyub Han
BACKGROUND: Radioembolization induced liver disease (REILD) is a possible sequela of transarterial radioembolization (TARE), particularly in cases of whole-liver treatment. To mitigate this problem, the safety and efficacy of combined transarterial chemoembolization (TACE) and TARE were evaluated for patients with bilobar hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Nineteen patients (mean age 60 years; range 27-82 years) treated for HCC between June 2012 and September 2014 were included in the analysis...
October 24, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29052747/angiosomal-radiopathologic-analysis-of-transarterial-radioembolization%C3%A2-for-the-treatment-of-hepatocellular-carcinoma
#20
Altan F Ahmed, Naziya Samreen, Joseph R Grajo, Ivan Zendejas, Chris L Sistrom, Amy Collinsworth, Ashwini Esnakula, Jehan L Shah, Roniel Cabrera, Brian S Geller, Beau B Toskich
PURPOSE: To assess the radiopathologic correlation following Yttrium-90 transarterial radioembolization (TARE) of hepatocellular carcinoma (HCC) using variable radiodosimetry to identify imaging surrogates of histologic response. METHODS: Twelve patients with HCC underwent ablative (≥ 190 Gy) and/or non-ablative (< 190 Gy) TARE delivered in a segmental, lobar, or combined fashion as a surgical neoadjuvant or bridge to transplantation. Both targeted tumor and treatment angiosome were analyzed before and after TARE utilizing hepatocyte-specific contrast-enhanced MRI or contrast-enhanced CT...
October 20, 2017: Abdominal Radiology
keyword
keyword
33486
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"